 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for making recommendations for the National Health Service on whether
drugs and other treatments represent a clinically and cost effective use of NHS resources.</p><p>NICE
has recommended the following drugs for the treatment of HER2-positive breast cancer:
trastuzumab emtansine (Kadcyla) for treating HER2-positive advanced breast cancer
after trastuzumab (Herceptin) and a taxane; pertuzumab (Perjeta) with trastuzumab
(Herceptin) and docetaxel for treating HER2-positive breast cancer; pertuzumab (Perjeta)
for the neoadjuvant treatment of HER2-positive breast cancer; and pertuzumab (Perjeta)
for adjuvant treatment of HER2-positive early stage breast cancer.</p><p>NHS commissioners
are legally required to fund drugs recommended in NICE technology appraisal guidance.
It is for clinicians to decide on the most appropriate treatment for an individual
patient based on their clinical judgement and in discussion with the patient.</p>
|
|
